Abbvie 

$0
32099
+$0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

25OctExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
2.27
2.5
2.72
2.95
Expected EPS
2.952384
Actual EPS
N/A

Financials

19.55%Profit Margin
Profitable
2017
2018
2019
2020
2021
2022
73.18BRevenue
14.31BNet Income

Analyst Ratings

$254.90Average Price Target
The highest estimate is 299.00.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
73%
Hold
27%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ABBV27. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Show more...
CEO
Mr. Robert A. Michael CPA
Employees
55000
Country
US
ISIN
XS2055646918

Listings

0 Comments

Share your thoughts

FAQ

What is Abbvie stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Abbvie stocks are traded under the ticker ABBV27.
What is Abbvie revenue for the last year?
Abbvie revenue for the last year amounts to 73.18B USD.
What is Abbvie net income for the last year?
ABBV27 net income for the last year is 14.31B USD.
How many employees does Abbvie have?
As of April 05, 2026, the company has 55,000 employees.
In which sector is Abbvie located?
Abbvie operates in the Health Care sector.
When did Abbvie complete a stock split?
Abbvie has not had any recent stock splits.
Where is Abbvie headquartered?
Abbvie is headquartered in North Chicago, US.